Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

Ipsen has turned to an­oth­er Paris-based bio­phar­ma com­pa­ny for its next CEO.

Sanofi Pas­teur chief David Loew — who’s been lead­ing one of the most ad­vanced ef­forts to de­vel­op vac­cines for Covid-19 — is mak­ing the jour­ney to Ipsen, 5 months af­ter David Meek jumped ship to run a start­up in late-stage de­vel­op­ment.

Loew ar­rives as Ipsen works to get back on track with their rare bone dis­ease drug palo­varotene, picked up in the $1.3 bil­lion Clemen­tia buy­out, which was slammed with a par­tial hold af­ter re­searchers ob­served cas­es of “ear­ly growth plate clo­sure” in pa­tients un­der the age of 14. But they are push­ing ahead with the over-14 crowd af­ter writ­ing down slight­ly more than half of its ini­tial de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER